The clearance also applies to an expanded indication in pediatric patients and use in the S1 trajectory. the company said. The implant is designed for sacroiliac fusion and sacropelvic fixation.
In 2022, the iFuse Bedrock Granite system earned its initial clearance. It also has the FDA’s Breakthrough Device Designation and a New Technology Add-on Payment from CMS.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
